Colorectal Cancer

Richard Kim, MD, discusses a real-world investigation of long-term responses with regorafenib in metastatic colorectal cancer.

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.

James Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.

Rona Yaeger, MD, discusses the rationale for launching an expansion cohort study based on findings from the CodeBreaK 101 study.

The combination of SCO-101 and FOLFIRI resulted in tumor reduction and increased progression-free survival in patients with metastatic colorectal cancer.

Rona Yaeger, MD, discusses a study of second-line sotorasib plus panitumumab in patients with KRAS G12C–mutated colorectal cancer.

Sebastian Stintzing, MD, discusses treatment with fruquintinib plus best supportive care in the Q-TWIST analysis in metastatic colorectal cancer.

Afsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.

Richard Kim, MD, discusses data from a real-world investigation of long-term responses with regorafenib in patients with metastatic colorectal cancer.

Adjuvant chemotherapy did not improve circulating tumor DNA clearance in patients with stage II colon cancer with baseline circulating tumor DNA.

Nivolumab/ipilimumab reduced the risk of disease progression or death vs chemotherapy in previously untreated patients with metastatic colorectal cancer.

Favorable ECOG PS, lower LDH levels, and absence of BRAF and KRAS mutations at baseline were associated with long-term response to regorafenib in patients with mCRC in the real world.

Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.

DKN-01/bevacizumab/chemotherapy had a tolerable safety profile and showcased clinical activity in patients with microsatellite stable colorectal cancer.

Neoadjuvant botensilimab/balstilimab led to robust responses in both patients with resectable mismatch repair–proficient and –deficient colorectal cancer.

An improvement in quality-adjusted survival benefit was observed with fruquintinib/BSC vs BSC alone in patients with mCRC enrolled in the FRESCO study.

The use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer from 2013 to 2022, especially in patients 50 years of age or younger.

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

The phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab in patients with microsatellite stable metastatic colorectal cancer will be discontinued due to futility.

Cathy Eng, M, FACP, FASCO, presents a comprehensive End-of-Year Review in Colorectal Cancer (CRC), delving into the exploration of emerging treatment options and clinical insights on the future landscape. This insightful review includes a focus on the recent approval of fruquintinib and important updates on target therapies for HER2+, BRAF V600E-Mutant, and KRAS-mutant CRC, as well as an interactive Q&A segment.

The combination of nivolumab and ipilimumab led to a statistically significant and clinically meaningful improvement in progression-free survival per blinded independent central review compared with investigator’s choice of chemotherapy as frontline therapy in patients with metastatic colorectal cancer.

The triplet combination of sintilimab, chidamide, and bevacizumab resulted in a high 18-week progression-free survival rate with a favorable toxicity profile in patients with microsatellite stable or mismatch repair–proficient metastatic colorectal cancer, according to data from the phase 2 CAPability-01 trial.

Pembrolizumab continued to demonstrate at trend toward improved overall survival compared with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.

SCO-101 in combination with leucovorin, fluorouracil, and irinotecan (FOLFIRI) prolonged survival in heavily pretreated patients with metastatic colorectal cancer who had no other active treatment options available, according to final data from part 2 of the phase 2 CORIST study.